HIV vaccine development in Canada
Edited by Eric Arts and Yong Gao
On December 14th and 15th 2016, in Ottawa, Ontario, the Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) hosted Canadian researchers to discuss past successes and current priorities related to advancing HIV vaccine research in Canada. About 30 Canadian scientists involved in vaccine research were joined by scientific representatives from the International and European AIDS vaccine initiatives (IAVI and EAVI2020, respectively), by keynote speakers Dr. William Schief from the Scripps Research Institute and Dr. Robin Shattock from Imperial College London, and by representatives from Canadian Federal government funding agencies, including the Public Health Agency of Canada (PHAC), Ministry of Health, and the Canadian Institutes of Health Research (CIHR).
The meeting featured a number of sessions highlighting the HIV vaccine research projects, both large and small, that have been funded by the CHVI over last 10 years. Our Canadian scientists are also internationally renowned researchers working in the area of HIV vaccine research with world leading strengths. Discussions amongst our research colleagues and invited guests, Drs. Schief and Shattock, identified a clear need for increased solidarity within the HIV vaccine research community, for enhanced partnerships with larger global vaccine consortia (e.g. IAVI and EAVI2020), and the need to highlight the incredible contributions by Canadian scientist to area of vaccine development. In relation to the latter, AIDS Research and Therapy has commissioned a special issue devoted to HIV vaccine-related research and entertained submission by Canadian researchers. This issue is not intended to highlight Canadian-centric research in this area but instead to showcase how Canadian scientist contribute to the overall goal of developing an effective HIV vaccine. The authors in this issue provide outstanding and clear opinions/reviews on key topics related to understanding the underlying factors for vaccine design, vaccine delivery strategies, adjuvants, and other prevention measures, as well as therapeutic vaccines.
This collection of articles has been partially sponsored. All articles have undergone the journal’s standard peer-review process. The Guest Editors declare no competing interests.
View all collections in AIDS Research and Therapy.